医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Lucence Launches DeepMARK™ for Profiling of SARS-CoV-2 Subgenomic RNA

2020年10月06日 PM09:00
このエントリーをはてなブックマークに追加


 

SINGAPORE

Molecular diagnostics company Lucence today announced the availability of the world’s first assay kit to directly profile SARS-CoV-2 subgenomic RNA (sgRNA), a marker of active viral replication1, from clinical samples. DeepMARK™ utilizes Lucence’s proprietary ultrasensitive next-generation sequencing (NGS) technology, AmpliMARK™, to concurrently detect and analyze the genome and transcriptome of SARS-CoV-2.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201006005415/en/

(Photo: Business Wire)

(Photo: Business Wire)

Pinpointing sources of unlinked SARS-CoV-2 cases supports rapid public health response. Using high-quality genetic fingerprinting, DeepMARK™ can enable rapid community case tracing by identifying transmission paths, clusters, and viral contagiousness. DeepMARK™’s increased sensitivity also allows for asymptomatic and recovering cases to be more thoroughly evaluated for contagiousness.

For researchers studying contagiousness, SARS-CoV-2 sgRNA is a recognized marker of active viral replication linked with contagiousness2 and offers several advantages. While viral culture is the gold standard, it is slow, expensive, and requires a biosafety level 3 (BSL3) laboratory, requirements prohibitive for the vast majority of samples. Using DeepMARK™, clinical samples can be safely and efficiently profiled using a simple workflow.

SgRNA as a marker of viral replication is also a well-recognized efficacy measurement in SARS-CoV-2 vaccine development3. Thus, comprehensive sgRNA profiling by DeepMARK™ could facilitate more efficient vaccine discovery.

“Genetic fingerprinting enables quicker and deeper analysis of viral spread. This tool has enhanced our capacity to understand SARS-CoV-2 precisely and contributes to the ongoing fight against COVID-19.” said A/Prof Hsu Li Yang, Vice Dean, Global Health, Saw Swee Hock School of Public Health, National University of Singapore.

DeepMARK™ is part of Lucence’s suite of SARS-CoV-2 molecular diagnostics. Lucence also makes the SAFER™ Sample Kit, a saliva stabilization kit with reported 36% higher sensitivity for detecting COVID-19 compared to nasopharyngeal swabbing4.

About DeepMARK™

DeepMARK™ is a next-generation sequencing (NGS) assay kit for the qualitative analysis of SARS-CoV-2 RNA. For Investigational Use Only. The performance characteristics of this product have not been established.

About Lucence

Lucence is a molecular diagnostics company that makes state-of-the-art, highly sensitive tests for disease detection and treatment selection. Headquartered in Singapore and California, Lucence’s services are delivered worldwide through an accredited central laboratory. For more information, contact enquiry@lucence.com or visit www.lucence.com/deepmark.

References

1. https://www.nature.com/articles/s41586-020-2196-x

2. https://wwwnc.cdc.gov/eid/article/26/11/20-3219_article

3. https://www.nejm.org/doi/full/10.1056/NEJMoa2024671

4. https://www.medrxiv.org/content/10.1101/2020.08.13.20173807v1

View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005415/en/

CONTACT

Gabriel Yap

media@lucence.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™